Product Description: Lufotrelvir (PF-07304814), a phosphate proagent of PF-00835231, acts as a potent 3CLpro protease (Mpro) inhibitor with SARS-CoV-2 antiviral activity. Lufotrelvir binds and inhibits SARS-CoV-2 3CLpro activity with a Ki of 174nM. Lufotrelvir is promising single antiviral agent and also can be used for the research of combination with other antivirals that target other critical stages of the coronavirus life cycle.
Applications: COVID-19-anti-virus
Formula: C24H33N4O9P
References: [1]Koen Vandyck, et al. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Curr Opin Virol. 2021 Apr 27;49:36-40./[2]Britton Boras, et al. Title: Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19 Short Title: Novel 3CL Protease Inhibitor for COVID-19
CAS Number: 2468015-78-1
Molecular Weight: 552.51
Compound Purity: 99.90
Research Area: Infection
Solubility: DMSO : 130 mg/mL (ultrasonic)/H2O : 50 mg/mL (ultrasonic)
Target: SARS-CoV
English
Deutsch
